Therapeutic Effect of Daleituzumab Combined with IRd Regimen on Patients with Relapsed and Refractory Multiple Myeloma
Objective To explore the effect of daleituzumab combined with IRd regimen in the treatment of patients with relapsed and refractory multiple myeloma(RRMM).Methods A total of 66 patients with RRMM admitted to our hospital from June 2019 to June 2022 were selected and randomly divided into two groups.The reference group was treated with IRd regimen(ixazomib+dexamethasone+lenalidomide),and the study group was treated with dasatuzumab on the basis of the reference group.The clinical efficacy,adverse reactions and recurrence rate were compared between the two groups.Results After 8 courses of treatment,the total remission rate of the study group was 93.94％,significantly higher than 57.58％of the reference group(P＜0.05).During the treatment period,no significant difference was found in the total incidence of adverse reactions between the study group(63.64％)and the reference group(45.45％),P＞0.05.During the 3-month follow-up period after treatment,the recurrence rate of the study group was 6.45％,significantly lower than 52.63％of the reference group(P＜0.05).Conclusions Daleituzumab combined with IRd regimen in the treatment of patients with RRMM has significant effect,which helps to reduce the recurrence rate and does not obviously increase the occurrence of adverse reactions.
DaleituzumabIRd regimenRelapsed and refractory multiple myelomaTherapeutic effectAdverse reaction
国家科技期刊平台
NSTL
万方数据
